Biotech News

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma (VOR)Vor BiopharmaCompany update

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on November 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 24,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 5,300 shares of Vor Bio’s common stock to 2 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Related news

Vor Biopharma

Autoimmune B-Cell Therapy Company Vor Bio is developing telitacicept for antibody-driven autoimmune diseases. Telitacicept Telitacicept is a recombinant fusion protein that inhibits both BAFF and APRIL, reducing survival signals for autoreactive B cells and plasma cells. Global Phase 3 Programs The UPSTREAM program is evaluating...

Recent company news

Stock data

Close
18.52 USD
Market cap
740.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States